MedPath

FDA Gives Positive Pre-IND Feedback for Novel mRNA Therapy Targeting Familial Hypercholesterolemia

• Repair Biotechnologies receives FDA support for their proposed Phase 1b clinical trial of REP-0003, an mRNA therapy designed to reduce atherosclerotic plaque in HoFH patients.

• Preclinical studies demonstrated significant plaque regression and improved exercise capacity in LDLR-knockout mice, showing promise for treating this rare genetic condition.

• The company's proprietary Cholesterol Degrading Platform technology aims to address the unmet medical need in HoFH patients who face early mortality from heart attacks and strokes.

Repair Biotechnologies has achieved a significant milestone in advancing its innovative mRNA therapy for treating homozygous familial hypercholesterolemia (HoFH), following positive feedback from the FDA during a Pre-IND meeting. The company's lead candidate, REP-0003, targets the critical unmet need in patients suffering from this rare genetic condition characterized by accelerated atherosclerosis.

Clinical Development Strategy

The FDA reviewers expressed alignment with Repair Biotechnologies' proposed clinical development program, specifically endorsing their clinical trial design, IND-enabling studies, and drug manufacturing processes. A key focus of the Pre-IND meeting was establishing appropriate clinical endpoints to demonstrate improved function in HoFH patients following REP-0003 treatment.
"HoFH remains a condition of high unmet need, reduced quality of life, and early mortality from plaque rupture leading to heart attack and stroke," stated Reason, CEO and Co-Founder of Repair Biotechnologies. "We hope to be able to make a real difference for this patient population."

Promising Preclinical Results

The therapeutic potential of REP-0003 has been demonstrated through preclinical studies using LDLR-knockout mice, which mirror the human condition through loss-of-function mutations in the low-density lipoprotein receptor gene. The studies showed significant and reliable regression of atherosclerotic plaque accompanied by improved exercise capacity - a crucial metric, as HoFH patients typically experience reduced exercise tolerance among other complications of accelerated atherosclerosis.

Innovative Technology Platform

REP-0003 was developed using Repair Biotechnologies' proprietary Cholesterol Degrading Platform (CDP), representing a novel approach to addressing toxic excess intracellular cholesterol in tissues. This platform technology provides a method to safely break down and eliminate this previously undruggable target, with potential applications extending beyond HoFH to conditions related to aging and obesity.
The planned Phase 1b study will focus on demonstrating the therapy's ability to reduce atherosclerotic plaque volume, with exercise capacity serving as a key functional endpoint. This approach aligns with the FDA's emphasis on meaningful clinical outcomes that directly impact patient quality of life.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cereno Scientific Advances CS1 Development Program with FDA Type C Meeting Request for PAH Treatment

Cereno Scientific has submitted a Type C meeting request to FDA following encouraging Phase IIa results for CS1, their HDAC inhibitor drug candidate for pulmonary arterial hypertension treatment.
The company aims to explore CS1's potential for reverse remodeling in PAH, with the FDA meeting expected within 75 days to align future development steps.

BioCardia Completes Low-Dose Cohort Enrollment in Novel CardiALLO Trial for Heart Failure Treatment

BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.
The groundbreaking trial utilizes allogeneic mesenchymal stem cells delivered through BioCardia's minimally invasive system, with the first Data Safety Monitoring Board review expected in March 2025.

HealthBio Launches FDA Fast-Track Trial for Long COVID Treatment Using Maraviroc-Atorvastatin Combination

HealthBio initiates Phase III clinical trial testing a novel combination of Selzentry (maraviroc) and Lipitor (atorvastatin) for Long COVID treatment, involving 252 patients in a randomized, double-blind study.
The company's approach targets vascular inflammation through CCR5 pathway modulation, supported by preliminary data showing promising results in over 12,000 treated patients.

AskBio's AB-1002 Gene Therapy Shows Promise in Heart Failure

AskBio's AB-1002 gene therapy demonstrates preliminary efficacy in treating congestive heart failure, with no serious adverse events reported in early clinical data.
The Phase 1 study (NAN-CS101) showed clinically meaningful improvements in left ventricular ejection fraction (LVEF) in a subset of patients with NYHA Class III heart failure.

Homozygous Familial Hypercholesterolemia Treatment Market to Surge by 2034

The Homozygous Familial Hypercholesterolemia (HoFH) treatment market, valued at approximately USD 108 million in 2022, is expected to grow significantly by 2034. With key players like Arrowhead Pharmaceutical and Novartis leading the charge, the market is set to benefit from increased disease prevalence, awareness, and the launch of innovative therapies. The FDA's recent approval of Evkeeza for children marks a pivotal advancement in HoFH treatment.

Arbor Biotechnologies' ABO-101 Receives FDA Clearance for Phase 1/2 Trial in Primary Hyperoxaluria Type 1

Arbor Biotechnologies' ABO-101, a CRISPR-based gene editing therapy, has been cleared by the FDA for a Phase 1/2 clinical trial in primary hyperoxaluria type 1 (PH1).
The redePHine trial will evaluate ABO-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in adult and pediatric patients with PH1.

Pharma Update: FDA Eases CGT Path, Tharimmune Surges on EMA Feedback, Lexeo Dips on Alzheimer's Data

The FDA is creating a more accessible regulatory environment for cell and gene therapy companies, according to executives at BioFuture 2024.
Tharimmune's stock soared following positive feedback from the EMA regarding its phase II study of TH-104 for pruritus associated with primary biliary cholangitis (PBC).

CellProthera Advances ProtheraCytes Cell Therapy Program for Myocardial Infarction with FDA Alignment on Phase III Trial Design

CellProthera has secured FDA alignment on the design for a pivotal Phase III trial of ProtheraCytes, a cell therapy for acute myocardial infarction (AMI).
The Phase III trial will be conducted in the US and Europe, involving a larger patient cohort with a two-year follow-up to assess long-term efficacy.

FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene-Editing Therapy for Primary Hyperoxaluria Type 1

Arbor Biotechnologies received FDA clearance for its Investigational New Drug (IND) application for ABO-101, a gene-editing therapeutic targeting primary hyperoxaluria type 1 (PH1).
The Phase 1/2 redePHine study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO-101 in adult and pediatric PH1 patients.

FDA Lifts Clinical Hold on Verve Therapeutics' VERVE-101 for HeFH

The FDA has cleared Verve Therapeutics' Investigational New Drug (IND) application for VERVE-101, allowing clinical trials in the U.S. to proceed.
VERVE-101 is a single-course, in vivo base editing medicine targeting the PCSK9 gene to durably lower LDL-C levels in patients.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy